IP Library Granted Patent US 10,456,455
Granted Patent B2
US 10,456,455 · App. 15/707,511 · Granted Oct 29, 2019

Treatment of psychological trauma

Inventors: Kenton B. Abel (Hacienda Heights, CA); Andrew M. Blumenfeld (Del Mar, CA)
Assignee: Allergan, Inc.
A61K38/4893
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,456,455
App. No.
15/707,511
Granted
Oct 29, 2019
Kind
B2
Abstract

The present specification discloses methods of treating a psychological trauma in an individual using botulinum toxins and/or a Targeted Exocytosis Modulator, and compositions thereof.

Claims (10)

1. A method of treating at least one symptom of post-traumatic stress disorder in a patient in need thereof, the method comprising the step of administering to the patient a therapeutically effective amount of a composition including a botulinum neurotoxin (BoNT), wherein administration of the composition decreases the at least one symptom of the post-traumatic stress disorder; and wherein the at least one symptom of post-traumatic stress disorder comprises total or partial amnesia of a traumatic event, flashbacks or nightmares wherein the patient re-experiences the traumatic event, avoidance of stimuli associated with the traumatic event, increased arousal including difficulty falling or staying asleep, anger, hyper-vigilance, or combinations thereof.

2. The method of claim 1 , wherein the BoNT is administered to an Arnold's nerve or a nerve from the recurrent laryngeal nerve complex.

3. The method of claim 1 , wherein the BoNT is administered to: the frontalis at divided among four sites of administration; to the corrugator divided among two sites of administration; to the procerus at one site of administration; to the occipitalis at six sites to eight sites of administration; to the temporalis at eight sites to ten sites of administration; to the trapezius at six sites to ten sites of administration and to the cervical paraspinal muscles at four sites of administration.

4. The method of claim 1 , wherein the BoNT is administered to the glabellar complex.

5. The method of claim 1 , wherein the BoNT is BoNT/A.

6. A method of treating at least one symptom of a psychological trauma disorder in a patient in need thereof, the method comprising the step of administering to the mammal in need thereof a therapeutically effective amount of a composition including a botulinum neurotoxin (BoNT) and/or a Targeted Exocytosis Modulator (TEM), wherein administration of the composition reduces the at least one symptom of the psychological trauma disorder, thereby treating the patient; wherein the psychological trauma disorder is a post-traumatic stress disorder, and wherein the at least one symptom is selected from the group consisting of total or partial amnesia, anger, avoidance of people, places or things that are reminders of the trauma, hypervigilance, insomnia, lack of concentration, emotional numbing, and a reduction in ability to participate in significant life activities including social relations and work.

7. The method of claim 6 , wherein the BoNT and/or TEM are administered to an Arnold's nerve or a nerve from the recurrent laryngeal nerve complex.

8. The method of claim 6 , wherein the BoNT and/or TEM are administered to: the frontalis at divided among four sites of administration; to the corrugator divided among two sites of administration; to the procerus at one site of administration; to the occipitalis at six sites to eight sites of administration; to the temporalis at eight sites to ten sites of administration; to the trapezius at six sites to ten sites of administration and to the cervical paraspinal muscles at four sites of administration.

9. The method of claim 6 , wherein the BoNT and/or TEM are administered to the glabellar complex.

10. The method of claim 6 , wherein the BoNT is BoNT/A.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 18, 2018
From: ABEL, KENTON B.; BLUMENFELD, ANDREW M.
To: ALLERGAN, INC.
Reel/Frame 046899/0571 →
Continuity (3)
Continuation 13495605 · Jun 13, 2012
Provisional Application 61496192 · Jun 13, 2011
Related Publication 20180000909A1 · Jan 4, 2018
Cited By (2)
US 12,364,740 US 12,533,400